Archives
-
ALOX5, Ferroptosis, and CRSwNP Barrier Dysfunction
2026-09-21
Huang et al. integrate endoplasmic-reticulum-stress gene analysis, network biology, machine learning, single-cell transcriptomics, and experimental validation to identify ALOX5 as a ferroptosis-associated marker linked to epithelial barrier injury in CRSwNP. The findings support a biologically plausible ALOX5–ferroptosis–barrier axis, while leaving important questions about causality, external validation, and therapeutic translation.
-
SGLT2 Cardioprotection: Class Effect or Drug Effect?
2026-09-21
A 2022 mouse study directly compared empagliflozin, dapagliflozin, and ertugliflozin during myocardial ischemia/reperfusion, separating urinary glucose-lowering activity from infarct protection. The findings implicate drug-specific mitochondrial, PI3K, and STAT3-associated signaling rather than SGLT2 inhibition alone, with implications for interpreting cardiometabolic evidence.
-
Ciclesonide: Respiratory Research Workflows
2026-09-20
Build reproducible asthma and allergic rhinitis assays around ciclesonide activation, glucocorticoid receptor binding, and lung-cell response measurements. A separate ERAD study provides a useful conceptual bridge for membrane-protein workflows—without confusing ciclesonide with the desonide-based degrader reported in that work.
-
Sulforaphane Workflows for Redox Research
2026-09-19
Sulforaphane connects Keap1–Nrf2 biology with practical assays for oxidative stress, inflammasome signaling, cancer chemoprevention, and cell death. This workflow translates mouse colitis findings into reproducible cell-based experiments while highlighting controls, dose selection, and troubleshooting decisions.
-
GDC-0941: From pAKT to Tumor Phenotype
2026-09-18
GDC-0941 is a selective PI3K inhibitor for connecting proximal PI3K/Akt pathway inhibition with cancer cell proliferation inhibition, apoptosis, and invasion phenotypes. This article provides an assay-interpretation framework inspired by a 2025 pancreatic cancer study while clearly separating direct evidence from testable hypotheses.
-
Adamtsl3, MMP9, and Adult Cortical Plasticity
2026-09-18
This study identifies Adamtsl3 as a cell-autonomous regulator of perineuronal-net integrity in parvalbumin-positive interneurons and links its loss to excessive MMP9 activity, reduced Otx2 uptake, oxidative stress, and renewed adult cortical plasticity. Its combination of mouse genetics, extracellular-matrix imaging, biochemical analysis, pharmacological rescue, and visual-cortex plasticity assays provides a mechanistic framework for studying schizophrenia-associated extracellular-matrix dysfunction.
-
CD28–ARS2–PKM Splicing and CD8+ T-Cell Metabolism
2026-09-17
The reference study identifies a CD28–ARS2 signaling axis that rewires alternative splicing of PKM in activated CD8+ T cells, favoring PKM2 and enabling flexible glucose metabolism, cytokine production, and antitumor activity. Its findings separate this splicing-dependent pathway from canonical CD28–PI3K signaling and provide a framework for integrating transcript, metabolic, and functional measurements.
-
CDK9 inhibitor A3294: Protocol and QC Guide
2026-09-17
CDK9 inhibitor A3294 is a selective serine/threonine kinase inhibitor for controlled studies of CDK9-dependent transcription elongation and exploratory HIV-1 propagation inhibition. It should not be treated as a pan-CDK reagent, a general cell-cycle inhibitor, or a basis for therapeutic conclusions.
-
DiscoveryProbe Protease Inhibitor Library: Assay Logic
2026-09-16
The DiscoveryProbe Protease Inhibitor Library supports protease inhibition studies from primary biochemical screening through cellular mechanism validation. This article presents an assay-decision framework that connects library composition, artifact control, orthogonal confirmation, and translational interpretation.
-
G007-LK Tankyrase 1/2 Inhibitor Workflow
2026-09-16
Build reproducible Wnt, β-catenin, and Hippo-pathway experiments with G007-LK, from concentration-response assays to mechanistic validation. This workflow connects APC-mutant colorectal cancer models with hepatocellular carcinoma assays while emphasizing controls, formulation, and troubleshooting.
-
Ertugliflozin Cardiovascular Outcomes in Type 2 Diabetes
2026-09-15
The VERTIS CV trial established that ertugliflozin was noninferior to placebo for major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Its rigorous endpoint hierarchy, long follow-up, and dose-pooled analysis provide a useful framework for interpreting cardiovascular, heart-failure, and renal signals in diabetes mellitus research.
-
U0126 and Adaptive Resistance in MEK1/2 Assays
2026-09-15
U0126 is a MEK1/2 inhibitor that reveals how MAPK/ERK blockade can be bypassed through AKT-dependent resistance. This article translates mechanistic findings on HDAC8, PLCB1, and DESC1 into a resistance-aware framework for cancer biology research and pathway assays.
-
Multiplex PBMC Flow Cytometry for Immunomodulator Screening
2026-09-14
Brox and Hackstein developed and validated a multiplex flow cytometry assay that measures T-cell proliferation and activation together with B-cell costimulatory responses in human PBMCs. The study shows how defined stimulation conditions, multiparametric readouts, and Z-factor validation can improve the physiological relevance and interpretability of immunomodulator screening.
-
GDC-0941 for PI3K/Akt Resistance Studies
2026-09-14
GDC-0941 provides a practical way to connect PI3K/Akt signaling with therapy resistance, cancer cell proliferation inhibition, and stem-like phenotypes. This workflow combines rapid pAKT pathway readouts with longer-term viability, apoptosis, β-catenin localization, and in vivo validation strategies.
-
EdU Imaging Kits (Cy3) for S-Phase Analysis
2026-09-13
EdU Imaging Kits (Cy3) use 5-ethynyl-2'-deoxyuridine and CuAAC labeling to measure DNA synthesis in S-phase cells without DNA denaturation. The K1075 workflow supports fluorescence microscopy and flow cytometry while preserving cellular morphology and antigen-binding sites.